The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling
about
Other targeted drugs in melanomaTherapeutic targeting of replicative immortalityTargeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263.Drug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicine.MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivoInhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancerCell cycle proteins as promising targets in cancer therapyOverview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.Cyclin-dependent kinases as therapeutic targets in melanoma.Dinaciclib for the treatment of breast cancer.Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.Targeting mitosis-regulating genes in cisplatin-sensitive and -resistant melanoma cells: A live-cell RNAi screen displays differential nucleus-derived phenotypes.Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors.Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines.Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
P2860
Q26775594-5DB15BBE-52EF-4E16-8129-6311AC92E6CDQ27027457-6684BD7F-82B5-4E25-87DC-418855B84DBFQ33415723-F78352FD-AE8B-4B18-A774-FB6F9E896AD2Q33876519-AF6411AB-B8D5-4C36-861E-D5C39AD2E54DQ34301314-EF61F1CF-8DC2-448A-B19F-C821D3839BE4Q35550068-C24BEC49-2F19-48C1-AB31-BC7E22DAB540Q36020882-9629AF46-CB27-477D-A1E8-020778E128F8Q36072490-E53778C8-CE3D-40EF-AC8C-5D96DBCF119BQ37636710-C1EDD2AD-46ED-4B71-9CF4-4BEC8F3EC12BQ37693690-8C2DEFC0-68DB-4C4C-A6FC-8F2470D2BA47Q38175443-2F9862E6-5A56-4DEE-B59B-B3B5264C007AQ38177036-99144657-FFEC-4128-95E7-C3C6300A677AQ38238282-D1381D2D-4A5F-4B77-B671-90187116F40BQ38734002-5F2C8EDD-266A-473D-B031-506F0503D550Q38886428-629F796E-F6E2-4EC4-BC6B-C6D4A3219C6FQ40041197-D1921937-49BB-4CF8-A8FF-C55BCFAC0C8EQ40061875-BB02B774-83E5-4A73-9553-3FAE52EE3327Q50031768-0F142BA1-F1EE-4828-A17D-544F341F27B2Q50042437-2B6B3380-3463-4A7E-8A4B-1AB45013CE15Q54322737-772DB96C-9057-4EEF-A7BF-6C4BED69CEE0
P2860
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The anti-melanoma activity of ...... is dependent on p53 signaling
@ast
The anti-melanoma activity of ...... is dependent on p53 signaling
@en
The anti-melanoma activity of ...... is dependent on p53 signaling
@en-gb
The anti-melanoma activity of ...... is dependent on p53 signaling
@nl
type
label
The anti-melanoma activity of ...... is dependent on p53 signaling
@ast
The anti-melanoma activity of ...... is dependent on p53 signaling
@en
The anti-melanoma activity of ...... is dependent on p53 signaling
@en-gb
The anti-melanoma activity of ...... is dependent on p53 signaling
@nl
prefLabel
The anti-melanoma activity of ...... is dependent on p53 signaling
@ast
The anti-melanoma activity of ...... is dependent on p53 signaling
@en
The anti-melanoma activity of ...... is dependent on p53 signaling
@en-gb
The anti-melanoma activity of ...... is dependent on p53 signaling
@nl
P2093
P2860
P50
P3181
P1433
P1476
The anti-melanoma activity of ...... is dependent on p53 signaling
@en
P2093
Brijal M Desai
Jessie Villanueva
Mercedes Lioni
Thierry-Thien K Nguyen
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0059588
P407
P577
2013-01-01T00:00:00Z